MDT-AP-3247
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- age_years
- 4.9
- sex
- M
- new_clusters
- C3
- umap1_2d
- 5.158144436
- umap2_2d
- 2.466507069
- umap1_3d
- 2.271637716
- umap2_3d
- -2.980780338
- umap3_3d
- -1.894050457
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.650
- G2M_CHECKPOINT+0.620
- MITOTIC_SPINDLE+0.440
- INTERFERON_ALPHA_RESPONSE+0.340
- MYC_TARGETS_V1+0.320
- MTORC1_SIGNALING+0.290
- PROTEIN_SECRETION+0.240
- SPERMATOGENESIS+0.240
- PI3K_AKT_MTOR_SIGNALING+0.210
- UNFOLDED_PROTEIN_RESPONSE+0.210
Top 10 suppressed
- MYOGENESIS-0.390
- COAGULATION-0.310
- HEDGEHOG_SIGNALING-0.310
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.300
- ESTROGEN_RESPONSE_EARLY-0.270
- KRAS_SIGNALING_DN-0.270
- HYPOXIA-0.250
- P53_PATHWAY-0.230
- COMPLEMENT-0.210
- ALLOGRAFT_REJECTION-0.190
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-B6-A1KN-01A-11R-A13Q-07 | — | C | 0.845 |
| 2 | d708a0d7-edda-46a8-b717-1b48c073c828 | — | — | 0.819 |
| 3 | MDT-AP-0415 | Med | Medulloblastoma | 0.815 |
| 4 | 9F4AEC07-5C91-4009-BA26-E4947CAA3391 | — | — | 0.813 |
| 5 | R392 | — | — | 0.809 |
| 6 | TCGA-91-6836-01A-21R-1858-07 | — | cohortA1 | 0.804 |
| 7 | SRR934882 | — | — | 0.802 |
| 8 | SRR934975 | — | — | 0.796 |
| 9 | MDT-AP-3245 | Med | Medulloblastoma | 0.794 |
| 10 | 7cec44f2-b56b-49fc-b2cc-d0691afde776 | — | — | 0.790 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.650 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.620 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.440 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.340 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.320 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.290 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.240 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.240 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.210 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.210 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.190 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.180 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.160 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.140 | Temsirolimus | — uncovered |
| MYC_TARGETS_V2 | 0.140 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.130 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.120 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.090 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.060 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.060 | Inavolisib | — uncovered |